Montgomery Investment Management Inc. Sells 498 Shares of Johnson & Johnson $JNJ

Montgomery Investment Management Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,231 shares of the company’s stock after selling 498 shares during the period. Johnson & Johnson makes up 1.1% of Montgomery Investment Management Inc.’s portfolio, making the stock its 24th biggest holding. Montgomery Investment Management Inc.’s holdings in Johnson & Johnson were worth $2,785,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of JNJ. EWA LLC lifted its stake in shares of Johnson & Johnson by 26.8% in the second quarter. EWA LLC now owns 2,860 shares of the company’s stock valued at $437,000 after buying an additional 604 shares during the period. Philip James Wealth Mangement LLC lifted its stake in Johnson & Johnson by 13.5% during the second quarter. Philip James Wealth Mangement LLC now owns 87,853 shares of the company’s stock worth $13,420,000 after purchasing an additional 10,438 shares during the period. Gold Investment Management Ltd. lifted its stake in Johnson & Johnson by 1.5% during the second quarter. Gold Investment Management Ltd. now owns 18,790 shares of the company’s stock worth $2,914,000 after purchasing an additional 279 shares during the period. Naples Global Advisors LLC raised its stake in shares of Johnson & Johnson by 3.5% in the second quarter. Naples Global Advisors LLC now owns 48,414 shares of the company’s stock valued at $7,395,000 after acquiring an additional 1,655 shares during the last quarter. Finally, Pure Financial Advisors LLC raised its stake in shares of Johnson & Johnson by 40.9% in the second quarter. Pure Financial Advisors LLC now owns 28,037 shares of the company’s stock valued at $4,283,000 after acquiring an additional 8,140 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Johnson & Johnson in a report on Saturday, September 27th. The Goldman Sachs Group upped their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Finally, Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $187.47.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $188.51 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $189.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.37 and a beta of 0.40. The company’s 50 day moving average price is $176.18 and its two-hundred day moving average price is $162.83.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm earned $2.82 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.